Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282787 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL6261277 | 0.91 | ALDH1A1 (0.72) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL20294664 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL20294662 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL6259464 | 0.88 | ALDH1A1 (0.57) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL8246241 | 0.88 | ALDH1A1 (0.46) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL7749984 | 0.87 | ALDH1A1 (0.56) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL6259763 | 0.86 | ALDH1A1 (0.52) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL6259576 | 0.86 | ALDH1A1 (0.54) | KDM4EALDH1A1POLBTP53GLA | |
| SCHEMBL3499274 | 0.86 | ALDH1A1 (0.77) | KDM4EALDH1A1POLBTP53GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-115282165-A | Natural killer cells from placenta | 细胞结构公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| CN-115137753-A | Natural killer cells from placenta | 细胞结构公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CELGENE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220026439-A1 | PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP | Orionis Biosciences BV (BE) | 2022-01-27 | — | — | US | disclosed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2022-01-06 | — | — | US | disclosed |
| US-20040091455-A1 | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004037199-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6380239-B1 | FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA | CELGENE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| US-6380239-B1 | FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA | CELGENE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| CN-1342146-A | Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels | CELGENE CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1342146-A | Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels | CELGENE CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | KDM4E 2282/4885ALDH1A1 3352/4885POLB 3591/4885 |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | KDM4E 2247/4885ALDH1A1 4281/4885POLB 3561/4885 |
| US-20220003749-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | BCL9, BCL9L, IKZF1 | KDM4E 873/4885ALDH1A1 2471/4885POLB 3700/4885 |
| US-11401336-B2 | BCMA-binding antibodies and uses thereof | CD79B, BCL6, CD22 | KDM4E 2282/4885ALDH1A1 3352/4885POLB 3591/4885 |
| US-20040091455-A1 | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration | MIF, IL2, PDE6D | KDM4E 2946/4885ALDH1A1 911/4885POLB 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.